Preclinical thyroid cancer study restores CAR-T target with targeted drugs
A preclinical Mayo Clinic study found that MAPK inhibitors restored TSHR on anaplastic thyroid cancer cells and improved tumor control ...
A preclinical Mayo Clinic study found that MAPK inhibitors restored TSHR on anaplastic thyroid cancer cells and improved tumor control ...
A new review maps the engineering strategies, from dual-target receptors to tumor microenvironment remodeling, that could finally bring CAR-T cell ...
Researchers in Düsseldorf report that co-expressing a non-signaling EGFR-binding CAR alongside EGFRvIII-specific CAR T-cells enhances killing of head and neck ...
Chimeric antigen receptor T cell therapy has transformed the treatment of certain blood cancers, delivering remissions in patients with leukemia ...
Physician-scientist Theodore Scott Nowicki, MD, PhD, an assistant professor in the departments of pediatrics hematology/oncology and microbiology, immunology, & molecular ...
At the forefront of cancer innovation, researchers from Memorial Sloan Kettering Cancer Center (MSK) showcased groundbreaking advancements at the 2026 ...
A groundbreaking advancement in cancer immunotherapy has emerged from the laboratories of Memorial Sloan Kettering Cancer Center (MSK), where scientists ...
A groundbreaking development in immunotherapy from UCLA scientists has unveiled a next-generation chimeric antigen receptor T-cell (CAR-T) therapy engineered to ...
In recent years, CAR T cell therapy has emerged as a groundbreaking approach in the fight against blood cancers, demonstrating ...
In the landscape of cancer immunotherapy, chimeric antigen receptor (CAR) T cell therapies have revolutionized treatment paradigms for hematological malignancies. ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine